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Iron Metabolism,
Anemia, and Heart Failure*
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Charleston, South Carolina
“When the heart is diseased, its work is imperfectly per-
formed; the vessels proceeding from the heart become
inactive so that you cannot feel them.” So goes one of the
cardiac glosses of the Ebers papyrus, written about 1600 BC
(1). This description is compatible with heart failure, and
this ancient author illustrates that careful clinical observa-
tion has long been a required predecessor to understanding
disease. So too has it been in recent years with the study of
anemia and iron metabolism in heart failure. Clinical
observations and basic mechanistic experiments have led to
clinical trials, which in turn have led to new observational
studies such as that by Okonko et al. (2) in this issue of the
Journal.
See page 1241
Iron is essential to life because it facilitates reversible
oxidation-reduction reactions. The most important of these
is the heme reaction, but iron is also a catalyst in many
enzymatic systems active in the heart, including cyto-
chromes, metalloproteinases, and so on (3). In its simplest
form, iron metabolism involves a continuous loop whereby
dietary, stored, or macrophage-recycled iron is transported
via transferrin to transferrin receptors and stored as ferritin,
in the marrow or in other organs. Abnormal iron absorption
can occur in both ischemic and nonischemic systolic heart
failure and can lead to clinical anemia (4). This is a
continuum, and there may be iron depletion without anemia
or even normal iron homeostasis with heart failure. When
iron deficiency is present, the classic laboratory findings
include low ferritin, normal or high total iron-binding
capacity (TIBC), and low transferrin saturation (TSAT)
(3). Alternatively, with anemia of chronic disease, there is
inadequate iron delivery despite adequate reserves (i.e., low
TSAT, high TIBC, and high or normal ferritin), common
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failure (4). There can be significant overlap, and other tools
for determining iron homeostasis include peripheral in-
dexes, marrow analysis, direct iron levels, and circulating
transferring receptor levels. Of course, patients with heart
failure may also have other causes of anemia, such as
bleeding, vitamin deficiency, hemolysis, drug reaction, ma-
lignancy, other chronic inflammatory conditions, and so on.
Reports on the incidence of anemia in heart failure
populations vary. A meta-analysis of 34 studies found the
average prevalence to be 37% (5). There are several theories
for why iron metabolism may be abnormal in heart failure.
Neurohormonal activation likely contributes. There may be
abnormal hepcidin-mediated gastrointestinal iron absorp-
tion, diversion of iron stores, decreased erythropoietin
response, hemodilution, or inflammatory cytokine activity
(4,6). For example, Nanas et al. (7) found anemia of chronic
disease in 73% of their patients with heart failure in terms of
depleted bone marrow stores despite normal iron, ferritin,
and erythropoietin levels. Unfortunately, our knowledge of
the pathophysiology of iron metabolism in heart failure is
incomplete, particularly in terms of always being able to
determine the etiology of anemia. What is clearer is that
worsening anemia in heart failure is an independent predic-
tor of mortality (8).
In this issue of the Journal, Okonko et al. (2) report their
study of 157 patients with chronic systolic heart failure (left
ventricular ejection fraction 45%), both ischemic and
nonischemic, in whom they categorized iron homeostasis
using standard peripheral laboratory measurements and
correlated these with known cardiac risk factors and out-
comes over a median follow-up period of over 2 years. The
investigators classified anemia as hemoglobin 13 g/dl for
men and 12 g/dl for women, with iron deficiency defined
as TSAT20%, TIBC45 mol/l, and ferritin30 g/l.
Low ferritin levels signified inadequate iron reserves and
were correlated with higher New York Heart Association
functional class. Anemia of chronic disease included ferritin
30 g/l (also analyzed at 100 g/l). Patients with both
nemia of chronic disease and iron-deficiency anemia were
efined as having TSAT 20% and ferritin 30 g/l.
erum transferrin receptor measurements were made in a
ohort to confirm findings.
The investigators found that 39% of their patients with
eart failure were anemic. Whether anemic or not, iron
eficiency (i.e., low TSAT in the face of adequate iron
tores (normal or high ferritin) was found in 43% of patients
nd was correlated with lower hemoglobin values and higher
ew York Heart Association functional class. Interestingly,
0% of nonanemic patients with heart failure had iron
eficiency, presumably identified before the development of
nemia. Among the patients with anemia, anemia of
hronic disease was found in 26%, iron-deficiency anemia
as present in 16%, and 17% had both concomitantly. Thenvestigators found that iron deficiency was correlated in-
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present or not), exercise intolerance, and higher risk for
death. Indeed, in patients with iron deficiency, those who
were anemic had twice the death rate of nonanemic patients
and 4 times the death rate of non–iron-deficient patients,
whether they were anemic or not. This study remains an
important refinement in understanding clinical iron homeo-
stasis independent of anemia in heart failure. The diag-
nostic distinction in iron-deficient patients between iron-
deficiency anemia, anemia of chronic disease, and, in
particular, both concomitantly was shown to provide
important prognostic information determined with read-
ily available clinical indexes (i.e., TSAT, hemoglobin,
TIBC, and ferritin).
Many of the advances in the heart failure field have taken
advantage of information gleaned from novel biomarkers.
However important, new biomarkers have limitations: they
may not be readily available, they may overlap with other
noncardiac diseases, clinicians may not be used to ordering
or interpreting them, data may be based on surrogate
endpoints, and in many cases they may not provide infor-
mation independent of traditional risk factors. This study,
and others, emphasizes the prognostic role of iron metab-
olism measurements, which may have just as useful a role
and are already widely available.
Left unanswered in an observational study is whether
treatment affects outcomes. There is evidence that improve-
ments in anemia may decrease symptoms and enhance left
ventricular function (8). For example, the recent FAIR-HF
(Ferinject Assessment in Patients With Iron Deficiency and
Chronic Heart Failure) trial (9) examined therapy with
intravenous iron in patients with heart failure with iron
deficiency (thereby bypassing any abnormal gastrointestinal
absorption) and found significant favorable responses in
symptoms and quality-of-life assessments. However, how,
if, or when treatment of anemia and/or iron deficiency in
heart failure should be done remains unclear in most clinical
situations. Ongoing trials with darbepoetin alfa and other
therapies are eagerly awaited (10). Until then, without clear
mortality data, the American College of Cardiology and
American Heart Foundation 2009 focused heart failure
guidelines update emphasizes that although anemia may be
associated with worsening heart failure, its correction has
not been established as therapy independent of other estab-
lished indications (11).So how does this study by Okonko et al. (2) improve our
management of heart failure? Whether written on papyrus
or in the Journal, careful observational studies are crucial to
advancement. The improved diagnostic accuracy demon-
strated is an argument for more patients with heart failure to
have their iron metabolism measured, especially as part of
research trials. This could better focus treatment results to
the type of iron dysregulation present. The hope is that one
day not too far off, abnormal iron homeostasis may become
one of the treatable aberrant metabolic pathways in the
heart failure syndrome.
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